Coherus Launches YUSIMRY, A Biosimilar Of Humira, For $995 Per Carton In U.S.
Portfolio Pulse from Benzinga Newsdesk
Coherus has launched YUSIMRY, a biosimilar of Humira, in the U.S. at a price of $995 per carton, representing a discount of over 85% compared to Humira. This move is expected to meet a high unmet need by providing patients, employers, physicians, and payers with low-cost access to adalimumab treatment.
July 03, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus's launch of YUSIMRY, a cheaper alternative to Humira, could potentially increase the company's market share and revenues in the short term.
The launch of YUSIMRY, a biosimilar of Humira, at a significantly lower price could attract a large number of patients, employers, physicians, and payers. This could potentially increase Coherus's market share and revenues in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100